Myoclonus associated with the use of gabapentin

Epilepsia

Volumn 41, Issue 4, 2000, Pages 479-481

  Asconapé, Jorge ^a   Diedrich, Andrea ^b   DellaBadia, John ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Carolina Neurological Clinic   (United States)

^c Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Anticonvulsants; Epilepsy; Gabapentin; Movement disorders; Myoclonus

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; CLORAZEPATE; GABAPENTIN; LORAZEPAM; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG EFFECT; DRUG RESPONSE; EPILEPSY; FEMALE; HUMAN; INCIDENCE; MALE; MYOCLONUS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0034127866     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb00192.x     Document Type: Article

References (8)

1. Asconapé J, Diedrich A, DellaBadia J. Gabapentin-associated myoclonus [Abstract]. Neurology 1995;45(suppl 4):A249-50.
2. Reeves AL, So EL, Sharbrough FW, Krahn LE. Movement disorders associated with the use of gabapentin. Epilepsia 1996;37:988-90.
3. Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996;46:852-3.
4. Pranzatelli MR. Serotonin and human myoclonus. Arch Neurol 1994;51:605-17.
5. Rao ML, Clarenbach P, Vahlensieck M, Krätzschmar S. Gubapentin augments whole blood serotonin in healthy young men. J Neural Transm 1988;73:129-34.
6. Taylor CP. Mechanisms of action of new anti-epileptic drugs. In: Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services, 1993; 13-40.
7. Goldlust A, Su TZ, Welty DF, Taylor CP, Oxender DL. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res 1995;22:1-11.
8. Kanthasamy AG, Vu TQ, Yun RJ, Truong DD. Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus. Eur J Clin Pharmacol 1996;297:219-24.